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a window of opportunity trial “hypoxia scan-nitroglycerin – 
hypoxia scan” (ClinicalTrials.gov Identifier: NCT01210378) 
and in the lab with a cellular respiration assays measuring 
Oxygen consumption (OCR) and extracellular acidification 
(ECAR) using Seahorse XF96 extracellular Flux analyser.  
Currently 19 patients have received their baseline HX-4 scan 
of which 14 patients received a second nitroglycerin scan as 
well. The median interval between the baseline and 
nitroglycerin scans was 4.5 days (range 2-7 days). 
We found that Nitroglycerin significantly decreases the 
hypoxic fraction in all investigated non-small cell lung cancer 
tumours and metastatic lymph nodes. Our lab work 
demonstrate that nitroglycerin has an inhibitory effect on 
mitochondrial respiration which by decreasing oxygen 
consumption increase the availability of oxygen and decrease 
hypoxia.  
This promising result encourages further investigation of 
nitroglycerin as a radio-sensitizing agent using hypoxia 
imaging as biomarker for selection. 
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Introduction: We have previously shown that αvβ3 integrins 
control radioresistance, hypoxia and angiogenesis and that 
co-expression of FGF-2 and  αvβ3 integrins in the tumors of 
patients treated with exclusive radio-chemotherapy for stage 
III non-small lung carcinoma (NSCLC), was associated with a 
worse local control, suggesting that inhibition of αvβ3 
integrin could induce a radiosensitization of such tumours. 
We designed a phase I trial associating the specific 
αvβ3/αvβ5 integrin inhibitor Cilengitide with radio-
chemotherapy in patients with stage III NSCLC.  
Patients and methods: A standard 3+3 dose escalation design 
was used. Cilengitide was given in continuous infusion 
starting 2 weeks before and then during the whole course of 
the radio-chemotherapy (66 Gy combined with a Platine-
Navelbine regimen), and then at a dose of 2000 mg twice a 
week in association with chemotherapy. Planed Cilengitide 
continuous infusion dose levels were 12, 18, 27 and 40 mg/h. 
PET-FDG and CT scan were performed before and then after 
the first two weeks of Cilengitide administration and then 2 
months after the end of radio-chemotherapy. Patients were 
followed by CT scan. Toxicity for DLT was assessed during 
combined treatment and until 1 month after. Clinical 
response on CT scan and TEP was evaluated according to 
RECIST and PERCIST criteria.  
Results: Fourteen patients were included between March 
2010 and July 2013. Eleven patients were evaluable for DLT. 
No DLT was observed at level 0, 1 and 2. One DLT, a  
tracheo-bronchial fistula was reported at the 40 mg/h dose. 
No relevant adverse event related to Cilengitide (7 grade 1 
and one grade 2) was observed on the whole population. 
Among 11 patients evaluable for efficacy, 9 patients 
presented a partial response and 2 a stable disease. At 12 
months after the end of radio-chemotherapy, 4 patients 
presented a progressive disease. At PET evaluation 2 months 
after radio-chemotherapy, 4 patients had a complete 
response and 4 patients had a partial response. 
Conclusion: Cilengitide given continuously with radio-
chemotherapy was well tolerated and shows encouraging 
clinical results, suggesting that targeting αvβ3 integrin 
continuously during radio-chemotherapy in NSCLC is a 
promising approach to treat this disease.  
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Moulds and Flaps are typically used on superficial skin 
brachytherapy for Planning Target Volume (PTV) up to 5 mm 
depth. In the cases of small and flat PTV, the use of 
superficial skin Applicators is an efficient solution because 
they shield the surrounding healthy tissues. In contrast to 
electrons beams applications (where bolus and specific 
dosimetry is required), treatment planning and delivery is 
simpler. 
 There are radionuclide-based HDR Ir-192 Applicators, as the 
Leipzig (Varian and Elekta) and Valencia (Elekta) ones. The 
Valencia Applicators are a modification of the Leipzig ones 
where a flattering filter has been added. Consequently, 
lateral homogeneity, penumbra, and useful beam are 
improved. However treatment time becomes longer. 
 The electronic HDR brachytherapy surface applicators offer 
an alternative to external beam electrons and HDR 
radionuclide brachytherapy modalities. There are currently 
two systems being used clinically: Xoft Axxent® (iCad) with 
50 kVp which has been in use since 2009 , and Esteya® 
(Elekta) with 69.5 kVp which has been released in 2014. We 
will discuss in this presentation our experience with the 
Esteya Unit, regarding commissioning, QA and clinical 
implementation. 
 Esteya is a new brachytherapy Unit designed to obtain dose 
distributions similar to Valencia App with an X-ray source of 
69.5 kVp. It has an adjustable arm and a set of 
interchangeable circular applicators of different diameters 
(10 mm, 15 mm, 20 mm, 25 mm, and 30 mm). Once overall 
absorbed dose, number of fractions, prescription depth and 
applicator size are selected in the console treatment 
planning system, the system presents automatically the 
treatment time. Compared with the Valencia Applicattors 
there are improvements in penumbra, treatment time, 
gradient on PTV and leakage. 
 The following aspects of commissioning will be discussed on 
this presentation: 
Timer: Reproducibility, accuracy and linearity (combined 
with mA) 
Flatness, symmetry and penumbra: Using radiochromic films 
and high spatial resolution array SRS1000 (PTW, Germany) 
HVL: Diode vs. ionization chamber detectors. Comparison of 
different set-ups 
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Absolute dose rate: Comparison of results and uncertainty 
analysis of a) using a chamber calibrated in air (A-20 from 
Standard Imaging calibrated on ADCL Wisconsin, USA) 
following the AAPM TG-61 protocol, and b) using a parallel 
plate chamber calibrated in water (TM34013 from PTW 
calibrated on PTW, Germany) following the IAEA TRS-398 
protocol. 
PDD: Using the parallel plate chamber on solid water. 
Leakage: Measurements at different levels with the primary 
beam blocked 
 The Esteya includes a specially designed QA tool that is 
connected to the exit of the X-ray tube. Each treatment day 
it is mandatory to perform a QA test before the first patient 
can be treated. This tool is composed of 26 diodes placed in 
two parallel planes, which are used to evaluate the output, 
flatness and percentage dose depth curve constancy at the 
same time. After the QA plan has been irradiated, the 
equipment console automatically shows the comparison with 
the reference values. Only if results are below an established 
tolerance level, the system allows patients to be treated. In 
addition, within a monthly basis, flatness, symmetry, 
penumbra, output and PDD are evaluated with film or high 
resolution array and parallel plate chamber on solid water. 
 Finally, the following clinical implementation aspects will be 
presented and discussed: depth evaluation (using High 
Frequency Ultrasound), margins and applicator selection, 
patient marking, patient set-up and treatment time 
calculation. 
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Background/Objective: Low and medium energy (kV) x-ray 
radiotherapy beams are still widely used for treatment, 
particularly for skin cancers and other relatively shallow 
lesions, and also more recently for ’electronic 
brachytherapy’ (Perez-Calatayud, this session).  Historically, 
kV beams have been used widely for radiobiology and related 
experiments, the results of which have been used to inform 
clinical radiotherapy practice, although the dosimetry has 
often been on less solid foundations than radiotherapy 
dosimetry. In the last ten years or so, since the increasingly 
wide availability of kV image guidance systems on clinical 
linacs, there has been a growing need for clear 
recommendations on kV beam dosimetry for these systems, 
where practical approaches have been developed which draw 
on both diagnostic radiology dosimetry and kV therapy beam 
dosimetry and with signficant contribution from MC modelling 
(Ding, this session).  Recently too, kV applications relevant to 
radiotherapy, in terms of supporting and developmental 
research, have included pre-clinical studies using small 
animal irradiators and microbeam methods, in both cases 
requiring small (or very small) kV beam dosimetry.  In general 
terms, the same quality standards are applicable in kV 
dosimetry as for high energy (MV) x-ray beams.  Thus, 
ideally, similar levels of precision and accuracy are required 
for treatment planning and delivery and hence similar levels 
of knowledge of beam characterisics and kV beam doses for 
both clinical and research uses, including for radiotherapy 
imaging beams.  Therefore, similar attention is necessary in 
choice of  instrumentation, experimental methods, beam 
calibration dosimetry, beam commissioning and quality 
assurance measurements, and their uncertainties.  kV beams 
should also be consisdered, as for MV beams, within the same 
general infrastructure of radiotherapy quality systems, 
clinical/quality audit and dosimetric audit.  
Overview Content: This overview considers the current 
situation in kV radiotherapy beam dosimetry and aims to 
cover: 
·       an outline of the specific requirements in kV dosimetry 
·       the instrumentation requirements for absolute and 
relative dose measurements in therapy beams 
·       the current dosimetry protocols and their similarities 
and differences, both for beam calibration protocols (in air 
and in phantom) and relative dosimetry recommendations 
·       phantoms and methods for measurements 
·       the likely uncertainties involved in methods and data 
·       the differences and similarities between dosimetry for 
kV beams when used for therapy or imaging 
·       the dosimetry methods used for kV CBCT 
·       MC in kV dosimetry, linking to Ding (this session) 
·       some comments on dosimetry needs and methods for 
novel kV applications, including  small animal systems and 
microbeams.  
Conclusions: The basis of kV dosimetry and the practical 
methods used are reasonably consistent with MV dosimetry, 
although uncertainties are typically greater.  Radiotherapy 
imaging dosimetry methods span different approaches which 
still needs further effort to  agree generally recommended 
and accepted guidelines.  Recent developments in pre-
clinical and microbeam applications have concentrated effort 
on small field kV dosimetry, which in turn also improves 
dosimetry for  standard clinical uses of kV radiotherapy 
beams.   All areas of kV beam dosimetry are benefiting 
greatly from MC modelling. 
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Introduction: The utilization of kV X-ray in image-guided 
radiotherapy (IGRT) has significantly improved the 
radiotherapy delivery accuracy and IGRT has become the new 
paradigm for patient positioning and target localization. Daily 
imaging procedures also add additional dose to the patients’ 
normal tissues. Knowledge of radiation dose resulting from a 
kV-CBCT scan and kV radiograph imaging procedures is 
important for clinicians in making informed decisions for 
treatment management and risk/benefit analysis.  
Purpose: The purpose of this presentation is  
1)      to describe the Monte Carlo simulation technique to 
generate kV beams from x-ray sources that are integrated to 
a radiotherapy treatment unit;  
2)      to show the beam characteristics of kV beams used in 
image guidance procedures;  
3)      to present the techniques to calculate dose to patients 
from kV-CBCT scans and kV radiograph imaging procedures by 
using the simulated kV beams 
4)      to give overview of Radiation dose to patients resulting 
from typical image-guided procedures 
5)      To discuss methods of managing and accounting for 
imaging guidance doses to radiotherapy patients 
Methods and Materials:  Although new model based 
calculation algorithms are being developed for model the 
radiation dose from low-energy x-ray beams, the Monte Carlo 
